Clinical Trial Update: Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of mirdametinib and vinblastine for newly diagnosed pediatric low-grade glioma with MAPK pathway activa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Mirdametinib (mirdametinib)
• Vinblastine (vinblastine)

Snippet

Sponsor: St. Justine's Hospital | Conditions: Pediatric Low-grade Glioma | Phase 1, Phase 2 | Status: RECRUITING